Genetic studies of melanocytic tumors have mainly demonstrated activation of oncogenes such as NRAS or BRAF through point mutations. In two cases of large congenital melanocytic nevi, we observed a chromosomal translocation involving the BRAF oncogene on chromosome 7q34, resulting in both cases in removal of the auto-inhibitory N-terminal regulatory domain (hence the Ras-guanosine triphosphate binding domain) of BRAF from its protein kinase domain. This is early evidence of BRAF activation through chromosomal translocation in melanocytic tumors. Because BRAF point mutations are rather rare in congenital melanocytic nevi and melanoma arising in non-sun-exposed area, the molecular mechanism of oncogenic activation as described here could be a...
Contains fulltext : 89081.pdf (publisher's version ) (Closed access)This review in...
According to the prevailing multistep model of melanoma development, oncogenic BRAF or NRAS mutation...
<div><p>According to the prevailing multistep model of melanoma development, oncogenic BRAF or NRAS ...
Genetic studies of melanocytic tumors have mainly demonstrated activation of oncogenes such as NRAS ...
Genetic studies of melanocytic tumors have mainly demonstrated activation of oncogenes such as NRAS ...
BRAF(V600E) mutations are frequent in melanomas originating from intermittently sun-exposed skin and...
We determined mutations in the BRAF, N-ras, and CDKN2A genes in 27 histologically diverse melanocyti...
Melanocytic nevi are thought to be senescent clones of melanocytes that have acquired an oncogenic B...
BRAFV600E mutations are frequent in melanomas originating from intermittently sun-exposed skin and a...
BRAFV600E mutations are frequent in melanomas originating from intermittently sun-exposed skin and a...
Extant evidence implicates growth factor signaling in the pathogenesis of many tumor types, includin...
Objective: V-raf murine sarcoma viral oncogene homolog B1 (BRAF), belongs to the family of V-RAF-1 m...
Mutations in the BRAF-gene are found in benign and malignant melanocytic lesions, >90% being a V599E...
A high frequency of activating BRAF somatic mutations have been identified recently in malignant mel...
According to the prevailing multistep model of melanoma development, oncogenic BRAF or NRAS mutation...
Contains fulltext : 89081.pdf (publisher's version ) (Closed access)This review in...
According to the prevailing multistep model of melanoma development, oncogenic BRAF or NRAS mutation...
<div><p>According to the prevailing multistep model of melanoma development, oncogenic BRAF or NRAS ...
Genetic studies of melanocytic tumors have mainly demonstrated activation of oncogenes such as NRAS ...
Genetic studies of melanocytic tumors have mainly demonstrated activation of oncogenes such as NRAS ...
BRAF(V600E) mutations are frequent in melanomas originating from intermittently sun-exposed skin and...
We determined mutations in the BRAF, N-ras, and CDKN2A genes in 27 histologically diverse melanocyti...
Melanocytic nevi are thought to be senescent clones of melanocytes that have acquired an oncogenic B...
BRAFV600E mutations are frequent in melanomas originating from intermittently sun-exposed skin and a...
BRAFV600E mutations are frequent in melanomas originating from intermittently sun-exposed skin and a...
Extant evidence implicates growth factor signaling in the pathogenesis of many tumor types, includin...
Objective: V-raf murine sarcoma viral oncogene homolog B1 (BRAF), belongs to the family of V-RAF-1 m...
Mutations in the BRAF-gene are found in benign and malignant melanocytic lesions, >90% being a V599E...
A high frequency of activating BRAF somatic mutations have been identified recently in malignant mel...
According to the prevailing multistep model of melanoma development, oncogenic BRAF or NRAS mutation...
Contains fulltext : 89081.pdf (publisher's version ) (Closed access)This review in...
According to the prevailing multistep model of melanoma development, oncogenic BRAF or NRAS mutation...
<div><p>According to the prevailing multistep model of melanoma development, oncogenic BRAF or NRAS ...